Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.58 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.51 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25831221 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL25831214 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL20065138 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL31424355 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL29033471 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL30477029 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL18198488 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL22654460 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL30477034 | 0.87 | KDM1A (0.58) | KDM1AKDM1BKCNH2SLC9A1RCOR1 | |
| SCHEMBL22654473 | 0.86 | KDM1A (0.57) | KDM1AKDM1BKCNH2SLC9A1RCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | Janssen Sciences Ireland Unlimited Company Co Cork, IE (IE) | 2022-11-08 | — | — | US | disclosed |
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN-CILAG (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN-CILAG (FR) | 2020-11-19 | — | — | US | disclosed |
| CN-111670189-A | Cycloalkyl-substituted pyrazolopyrimidines having activity on RSV | 爱尔兰詹森科学公司 | 2020-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | ACE, ACE2, PTBP1 | KDM1A 3168/4885KDM1B 3491/4885KCNH2 1886/4885 |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | ACE, ACE2, PTBP1 | KDM1A 3024/4885KDM1B 3355/4885KCNH2 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.